PD1/PD-L1 targeting in advanced soft-tissue sarcomas: a pooled analysis of phase II trials

Immune checkpoint inhibitors, especially the programmed cell death receptor-1/ligand 1 (PD-1/L1) inhibitors, displayed promising efficacy in several solid tumor types and hematological malignancies. Data related to their activity in soft-tissue sarcomas (STS) are scarce. We performed a pooled analys...

Descripción completa

Detalles Bibliográficos
Autores principales: Italiano, Antoine, Bellera, Carine, D’Angelo, Sandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7236113/
https://www.ncbi.nlm.nih.gov/pubmed/32430039
http://dx.doi.org/10.1186/s13045-020-00891-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7236113/
https://www.ncbi.nlm.nih.gov/pubmed/32430039
http://dx.doi.org/10.1186/s13045-020-00891-5

Ejemplares similares